BioStem CFO reports options and RSU holdings

BioStem Technologies, Inc. reported the initial equity holdings of its Chief Financial Officer, Brandon Poe.

Rhea-AI Filing Summary

BioStem Technologies, Inc. reported the initial equity holdings of its Chief Financial Officer, Brandon Poe. He holds stock options to acquire 38,814 shares of common stock at an exercise price of $6.48 expiring on August 19, 2035, and options over 117,401 shares at $5.50 expiring on February 11, 2036. These options vest 33% on the first anniversary of their respective grant dates, with the balance vesting in equal quarterly installments over the following two years. Poe also holds restricted stock units covering 8,469, 32,225, and 96,909 shares of common stock, each series vesting in equal quarterly installments over three years from its grant date or 33% after one year with the remainder vesting quarterly over the next two years, as applicable. Each restricted stock unit represents a contingent right to receive one share of common stock. In addition, he directly owns 45,734 shares of common stock.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider POE BRANDON

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F2	--	--	--
holding	Restricted Stock Units F4, F3	--	--	--
holding	Restricted Stock Units F4, F5	--	--	--
holding	Restricted Stock Units F4, F6	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 156,215 contracts (Direct); Restricted Stock Units — 137,603 contracts (Direct); Common Stock — 45,734 shares (Direct)

Footnotes (6)

1. F1. These options vest according to the following schedule: 33% will vest on August 19, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
2. F2. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
3. F3. These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
4. F4. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
5. F5. These restricted stock units vest according to the following schedule: 33% will vest on August 19, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
6. F6. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

Key Figures

Stock options at $6.48: 38,814 shares Stock options at $5.50: 117,401 shares RSU grant 1: 8,469 units +5 more

8 metrics

Stock options at $6.48 38,814 shares Options to buy common stock at $6.48 expiring August 19, 2035

Stock options at $5.50 117,401 shares Options to buy common stock at $5.50 expiring February 11, 2036

RSU grant 1 8,469 units Restricted stock units vesting quarterly over three years from September 15, 2024

RSU grant 2 32,225 units Restricted stock units vesting 33% after one year, then quarterly over two years

RSU grant 3 96,909 units Restricted stock units vesting 33% after one year, then quarterly over two years

Direct common shares 45,734 shares Direct ownership of BioStem Technologies common stock

Option expiration 1 August 19, 2035 Expiration date for options over 38,814 shares at $6.48

Option expiration 2 February 11, 2036 Expiration date for options over 117,401 shares at $5.50

Key Terms

Stock Option (Right to Buy), Restricted Stock Units, exercise price, contingent right to receive one share, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) with exercise prices and expirations"

Restricted Stock Units financial

"security_title: Restricted Stock Units tied to common stock vesting over time"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"conversion_or_exercise_price: 6.4800 and 5.5000 for stock option grants"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

contingent right to receive one share financial

"Each restricted stock unit represents a contingent right to receive one share"

vesting in equal quarterly installments financial

"units vest in equal quarterly installments over the subsequent two year period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BioStem Technologies (BSEM) disclose about CFO Brandon Poe’s stock options?

BioStem Technologies discloses that CFO Brandon Poe holds stock options over 38,814 shares at $6.48 expiring August 19, 2035, and 117,401 shares at $5.50 expiring February 11, 2036. Both grants vest 33% after one year, then quarterly over two additional years.

How many restricted stock units does BSEM’s CFO Brandon Poe hold?

CFO Brandon Poe holds restricted stock units tied to 8,469, 32,225, and 96,909 shares of BioStem Technologies common stock. Each restricted stock unit represents a contingent right to receive one share and vests in scheduled installments over three years from the respective grant dates.

What are the vesting terms for Brandon Poe’s restricted stock units at BioStem Technologies (BSEM)?

Some restricted stock units vest in equal quarterly installments over three years from the September 15, 2024 grant date. Other RSU grants vest 33% on the one-year anniversary of their grant dates, with remaining units vesting in equal quarterly installments over the subsequent two years.

How many BioStem Technologies (BSEM) common shares does CFO Brandon Poe directly own?

CFO Brandon Poe directly owns 45,734 shares of BioStem Technologies common stock. This direct ownership is reported in addition to his stock options and restricted stock units, which, if and when vested and exercised or settled, could further increase his economic exposure to the company’s equity.

Does the Form 3 for BSEM show any recent insider buying or selling by the CFO?

The Form 3 for BioStem Technologies lists holdings only and shows no explicit buy or sell transactions for CFO Brandon Poe. It details his existing stock options, restricted stock units, and common stock position as of the reported date without recording market purchases or sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 07:10 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

POE BRANDON

(Last) (First) (Middle)

C/O BIOSTEM TECHNOLOGIES, INC.

2836 CENTER PORT CIRCLE

(Street)

POMPANO BEACH FLORIDA 33064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	45,734	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	08/19/2035	Common Stock	38,814	$6.48	D
Stock Option (Right to Buy)	(2)	02/11/2036	Common Stock	117,401	$5.5	D
Restricted Stock Units	(3)	(3)	Common Stock	8,469	(4)	D
Restricted Stock Units	(5)	(5)	Common Stock	32,225	(4)	D
Restricted Stock Units	(6)	(6)	Common Stock	96,909	(4)	D

Explanation of Responses:

1. These options vest according to the following schedule: 33% will vest on August 19, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

2. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

3. These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).

4. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

5. These restricted stock units vest according to the following schedule: 33% will vest on August 19, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

6. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

	/s/ Brandon Poe	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)